Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients

UROS MARKOVIC, ANNA BULLA, SALVATORE LEOTTA, STEFANIA STELLA, MARIA LETIZIA CONSOLI, LOREDANA TAMBÈ, CONCETTA CONTICELLO, FRANCESCO DI RAIMONDO and FABIO STAGNO
Anticancer Research September 2020, 40 (9) 5313-5317; DOI: https://doi.org/10.21873/anticanres.14538
UROS MARKOVIC
1Hematology Section and BMT Unit, Rodolico Hospital, AOU Policlinico - V. Emanuele, Catania, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANNA BULLA
1Hematology Section and BMT Unit, Rodolico Hospital, AOU Policlinico - V. Emanuele, Catania, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SALVATORE LEOTTA
1Hematology Section and BMT Unit, Rodolico Hospital, AOU Policlinico - V. Emanuele, Catania, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEFANIA STELLA
2Center of Experimental Oncology and Hematology, Department of Clinical and Experimental Medicine, AOU Policlinico - V. Emanuele, University of Catania, Catania, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARIA LETIZIA CONSOLI
1Hematology Section and BMT Unit, Rodolico Hospital, AOU Policlinico - V. Emanuele, Catania, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LOREDANA TAMBÈ
1Hematology Section and BMT Unit, Rodolico Hospital, AOU Policlinico - V. Emanuele, Catania, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CONCETTA CONTICELLO
1Hematology Section and BMT Unit, Rodolico Hospital, AOU Policlinico - V. Emanuele, Catania, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FRANCESCO DI RAIMONDO
1Hematology Section and BMT Unit, Rodolico Hospital, AOU Policlinico - V. Emanuele, Catania, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FABIO STAGNO
1Hematology Section and BMT Unit, Rodolico Hospital, AOU Policlinico - V. Emanuele, Catania, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: fsematol@tiscali.it
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Imatinib (IM) is the standard-of-care treatment for most chronic myeloid leukemia (CML) patients in chronic phase (CP). However, some patients suffer from low-grade side-effects that, in the long run, severely affect the quality of life and require treatment discontinuation due to toxicities. Fortunately, there are several therapeutic alternatives for these patients. Among them, the second-generation tyrosine kinase inhibitor dasatinib (DAS), used as second-line treatment, has shown to be a valid option in patients with CP-CML after intolerance to prior IM. Patients and Methods: Herein, we report on seven CP-CML patients who achieved a stable major molecular response (MMR) with IM-therapy, but were shifted to DAS treatment due to recurrent low-grade IM-intolerances (grades 1-2). Results and Conclusion: All patients received conventional DAS treatment with a median daily dose of 83.3 mg. Treatment was well tolerated and side-effects were mild. In addition, after a median follow-up of 25 months (range=24-43 months) a deep molecular response (DMR) (either MR4 or MR4.5) was achieved in all patients after 24 months of treatment. This finding, although limited to a small cohort of CP-CML patients, supports the view that a therapy switch from IM to DAS induces a reduction of symptom burden, improves patient compliance and shows clinical efficacy in achieving and sustaining deep molecular responses.

  • Imatinib
  • chronic myeloid leukemia
  • dasatinib
  • second-line treatment
  • TKI
  • BCR-ABL1

The clinical scenario of chronic myeloid leukemia (CML) has changed significantly, since the introduction of tyrosine kinase inhibitors (TKIs) therapy. In most cases, CML has become a chronic disease, requiring both long-term treatment and molecular monitoring, allowing patient life expectancy to approach that of the general population (1) and driving them to achieve deep molecular response (DMR) in a substantial number of cases (2). Evidence has shown that most CML patients in chronic phase (CP-CML) who have achieved a stable DMR can safely discontinue TKI treatment (3). However, in the clinical aspect, a proportion of CP-CML patients had to change TKIs treatment due to the occurrence of adverse events, thus affecting the achievement of either clinical or molecular responses (4).

The classic trial International Randomized Study of Interferon and STI571 (IRIS) compared interferon-alpha combined with low-dose cytarabine therapy to imatinib (IM) 400 mg daily in newly-diagnosed CP-CML patients (5). In that investigation IM displayed markedly superior rates of complete hematological response, complete cytogenetic response (CCyR), major molecular response (MMR) and freedom from disease progression to advanced phases. In the long term, patients assigned to the IM group showed an estimated overall survival rate of 83.3% at 10 years (6). At 5 years of follow-up 49.9% of the patients had a CCyR, 50.3% of them reached a MMR and 23% a deep molecular response (MR4.5), while at 10 years of follow-up 34.4% of patients displayed a MMR and 23.3% had a MR4.5 (all data on intention to treat population). However, at the last update of this trial, 49.2% of the enrolled patients discontinued IM-therapy and in 6.9% of them it was due to adverse events (AE).

Persistent low-grade AEs may prevent patients with CP-CML from continuing TKIs therapy and can adversely impact both their quality of life (7) as well as clinical efficacy (8). In this era, the availability of second-generation TKIs has been helpful as an alternative regimen in all cases of intolerance/resistance to IM-therapy (9). Herein, we report on the efficacy of dasatinib (DAS) therapy used as second-line treatment in both improving quality of life and inducing deep molecular responses (DMR) in IM-intolerant CP-CML patients who were in stable MMR.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Patient characteristics at diagnosis and previous Imatinib treatment.

Patients and Methods

Seven patients with CP-CML (Table I) treated with IM showed persistent low-grade AEs that seriously affected their quality of life. Median age at CML diagnosis was 53 years (range=46-66 years), with a male/female ratio of 4/3. According to Sokal score patients were the following: three high-risk, two intermediate-risk and one low-risk patient; while according to EUTOS long term survival (ELTS) score: three had intermediate-risk and three low-risk score. One patient was not stratified for prognostic scores because of previous CML-unrelated splenectomy. Bone marrow cytogenetics showed the presence of the Philadelphia chromosome in all patients and one of them exhibited trisomy 8. BCR-ABL1 transcript type was e14a2 in five out of seven and e13a2 in two patients. BCR-ABL1 transcript levels were assessed at baseline and every 3 months, and transcript values were measured from peripheral blood samples using real-time PCR (RT-qPCR) using ABL1 as the reference gene at any time. BCR-ABL/GUSIS was also evaluated at diagnosis, as previously reported, and high levels of BCR-ABL/GUSIS were present in three patients, while the others showed low transcript levels (10). All molecular responses were categorized according to common accepted guidelines (11).

After informed consent, patients were started on conventional IM-therapy with a median duration of 61 months (range=14-144 months). All obtained an optimal response within 18 months of treatment according to ELN recommendations (12), but soon began to experience IM-related AEs. The most common were diarrhea, muscle spasms and periorbital edema. Intolerances were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (13).

Persistent AEs, although low grade, impacted seriously the patients' quality of life and therefore standard DAS treatment (100 mg/day) was administered. Median DAS daily dose was 83.3 mg with a median follow-up of 25 months (range=24-43 months). Six out of seven patients showed a stable MMR before commencing DAS-therapy. In fact, one patient had a MR4, although with a fluctuating molecular response between MMR and MR4. After switching to DAS treatment five patients out of seven achieved a DMR at 12-months (3 gained MR4 and two MR4.5) and median time to achieve DMR was 4.5 months (range=3-21 months). Then, at 18-, 21- and 24-months a DMR was reached by 4 out of 7, 6/7 and 7/7 patients. All patients experienced low grade AEs (grade 1-2), but not persistent and no grade 3/4 event was recorded (Table II). Grade 2 toxicity was resolved with dose reduction (50 mg/day) in five patients (71%). Most common DAS-related side effects were fatigue in five patients, myalgia and pleural effusion in four patients, and pericardial effusion in three patients. Infections (pulmonary and urinary tract), pleural and pericardial effusions were present in two patients, respectively. No patient had to discontinue DAS therapy because of AEs and these events did not affect their quality of life.

Results and Conclusion

The introduction of TKIs therapy revolutionized treatment and clinical outcomes in CP-CML. Nevertheless, because of long-term treatment, different rates of AEs have been described and recurrent AEs have become an important cause of quality of life impairment, lack of compliance and finally treatment discontinuation (6, 14-18). We, herein, describe seven patients who suffered from persistent low-grade AEs that impaired seriously their every-day living activities and had to discontinue IM-treatment being switched to DAS therapy. A recent investigation showed that CML patients in IM therapy reported worse disease-specific health-related quality of life outcome and symptom burden as compared to DAS treatment (19). Moreover, a prospective study showed that switching from IM to DAS because of intolerance, greatly improved patients' quality of life, leading to better compliance, despite the onset of DAS-related AEs (20). Another study on IM-intolerant patients revealed grade 3-4 AEs cross-intolerance in a minority of patients treated subsequently with DAS, while attaining improvements in both cytogenetic and molecular response (21). In our small cohort, we observed a reduction of both hematological and non-hematological AE rates, including muscle spasms and diarrhea, with no patient representing periorbital edema. On the other hand, despite the emergence of DAS-related AEs, like pleural and pericardial effusion, we noted that these AEs did not severely affect the patient's quality of life.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Therapy-related adverse events.

Second-generation TKIs and the new third-generation ponatinib have been already approved as second-line treatment and have demonstrated efficacy in the setting of CML resistance/intolerance (18, 22-24). Conversely, few studies investigated a molecular improvement from a baseline MMR. The first study investigated the efficacy of nilotinib (NIL) in CP-CML patients intolerant to first-line treatment with IM or DAS and not in DMR: only 45% of the enrolled patients had MMR baseline and were not assessed sequentially (25). In the same way the Evaluating Nilotinib Efficacy and Safety in clinical Trials-Complete Molecular Response (ENESTcmr) study investigated patients having not only CCyR, but also persistent minimal residual disease (either with or without MMR baseline) (26). The Nilotinib Switch (NILSw) trial showed the efficacy of switching to NIL treatment in CP-CML patients who had previously achieved MMR with IM therapy (27). Among thirty-eight patients enrolled in study, the cumulative incidence of achieving MR4.5 was 53.7% by 21 months.

Our data are consistent with “real life” data showing that DAS therapy might represent a safe and effective option for patients resistant/intolerant to IM (28-29) as well as it induces clinical efficacy also in atypical transcripts (30). Moreover, it was recently demonstrated as DAS treatment, as first-line therapy, indicated a significantly lower impact on CML patients' daily life as compared to their peers treated with IM (19).

In conclusion, our finding, although limited to a small group of CP-CML patients, supports the view that a therapy switch from IM to DAS induces a reduction of symptom burden, improves compliance and might be of aid in achieving deep molecular responses after a baseline MMR obtained previously with IM-therapy, making it possible for more candidates a treatment free remission path.

Footnotes

  • Authors' Contributions

    UM and FS drafted the manuscript; UM, AB, SL, CC and FS managed the patients, analyzed and interpreted the data; SS, MLC and LT performed laboratory tests; FDR and FS supervised the clinical project. All Authors have seen and approved the final version of the manuscript.

  • Conflicts of Interest

    The Authors declare that they have no competing interests.

  • Received June 15, 2020.
  • Revision received July 9, 2020.
  • Accepted July 10, 2020.
  • Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Bower H,
    2. Björkholm M,
    3. Dickman PW,
    4. Höglund M,
    5. Lambert PC,
    6. Andersson TML
    : Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34(24): 2851-2857, 2016. PMID: 27325849. DOI: 10.1200/JCO.2015.66.2866
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Hochhaus A,
    2. Baccarani M,
    3. Silver RT,
    4. Schiffer C,
    5. Apperley JF,
    6. Cervantes F,
    7. Clark RE,
    8. Cortes JE,
    9. Deininger MW,
    10. Guilhot F,
    11. Hjorth-Hansen H,
    12. Hughes TP,
    13. Janssen JJWM,
    14. Kantarjian HM,
    15. Kim DW,
    16. Larson RA,
    17. Lipton JH,
    18. Mahon FX,
    19. Mayer J,
    20. Nicolini F,
    21. Niederwieser D,
    22. Pane F,
    23. Radich JP,
    24. Rea D,
    25. Richter J,
    26. Rosti G,
    27. Rousselot P,
    28. Saglio G,
    29. Saußele S,
    30. Soverini S,
    31. Steegmann JL,
    32. Turkina A,
    33. Zaritskey A,
    34. Hehlmann R
    : European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34: 966-984, 2020. PMID: 32127639. DOI: 10.1038/s41375-020-0776-2
    OpenUrl
  3. ↵
    1. Mahon FX
    : Treatment-free remission in CML: Who, how, and why? Hematology Am Soc Hematol Educ Program 2017(1): 102-109, 2017. PMID: 29222243. DOI: 10.1182/asheducation-2017.1.102
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Steegmann JL,
    2. Baccarani M,
    3. Breccia M,
    4. Casado LF,
    5. Garcìa-Gutiérrez V,
    6. Hochhaus A,
    7. Kim W,
    8. Kim TD,
    9. Khoury HJ,
    10. le Coutre P,
    11. Mayer J,
    12. Milojkovic D,
    13. Porkka K,
    14. Rea D,
    15. Rosti G,
    16. Saussele S,
    17. Hehlmann R,
    18. Clark RE
    : European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 30(8): 1648-1671, 2016. PMID: 27121688. DOI: 10.1038/leu.2016.104
    OpenUrl
  5. ↵
    1. O'Brien SG,
    2. Guilhot F,
    3. Larson RA,
    4. Gathmann I,
    5. Baccarani M,
    6. Cervantes F,
    7. Cornelissen JJ,
    8. Fischer T,
    9. Hochhaus A,
    10. Hughes T,
    11. Lechner K,
    12. Nielsen JL,
    13. Rousselot P,
    14. Reiffers J,
    15. Saglio G,
    16. Shepherd J,
    17. Simonsson B,
    18. Gratwohl A,
    19. Goldman JM,
    20. Kantarjian H,
    21. Taylor K,
    22. Verhoef G,
    23. Bolton AE,
    24. Capdeville R,
    25. Druker BJ,
    26. IRIS Investigators
    : Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11): 994-1004, 2003. PMID: 12637609. DOI: 10.1056/NEJMoa022457
    OpenUrlCrossRefPubMed
  6. ↵
    1. Hochhaus A,
    2. Larson RA,
    3. Guilhot F,
    4. Radich JP,
    5. Branford S,
    6. Hughes TP,
    7. Baccarani M,
    8. Deininger MW,
    9. Cervantes F,
    10. Fujihara S,
    11. Ortmann CE,
    12. Menssen HD,
    13. Kantarjian H,
    14. O'Brien SG,
    15. Druker BJ,
    16. IRIS Investigators
    : Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376(10): 917-927, 2017. PMID: 28273028. DOI: 10.1056/NEJMoa1609324
    OpenUrlCrossRefPubMed
  7. ↵
    1. Pinilla-Ibarz J,
    2. Cortes J,
    3. Mauro MJ
    : Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications. Cancer 117(4): 688-697, 2011. PMID: 20922786. DOI: 10.1002/cncr.25648
    OpenUrlCrossRefPubMed
  8. ↵
    1. Jabbour EJ,
    2. Kantarjian H,
    3. Eliasson L,
    4. Megan Cornelison A,
    5. Marin D
    : Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol 87(7): 687-691, 2012. PMID: 22473898. DOI: 10.1002/ajh.23180
    OpenUrlCrossRefPubMed
  9. ↵
    1. Jabbour E,
    2. Kantarjian H,
    3. Cortes J
    : Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: An evolving treatment paradigm. Clin Lymphoma Myeloma Leuk 15(6): 323-334, 2015. PMID: 25971713. DOI: 10.1016/j.clml.2015.03.006
    OpenUrlCrossRefPubMed
  10. ↵
    1. Vigneri P,
    2. Stagno F,
    3. Stella S,
    4. Cupri A,
    5. Forte S,
    6. Massimino M,
    7. Antolino A,
    8. Siragusa S,
    9. Mannina D,
    10. Impera SS,
    11. Musolino C,
    12. Malato A,
    13. Mineo G,
    14. Tomaselli C,
    15. Murgano P,
    16. Musso M,
    17. Morabito F,
    18. Molica S,
    19. Martino B,
    20. Manzella L,
    21. Müller,
    22. Hochhaus A,
    23. Di Raimondo F
    : High BCR–ABL/GUSIS levels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib. Clin Cancer Res 23(23): 7189-7198, 2017. PMID: 28928163. DOI: 10.1158/1078-0432.CCR-17-0962
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Cross NCP,
    2. White HE,
    3. Müller MC,
    4. Saglio G,
    5. Hochhaus A
    : Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26(10): 2172-2175, 2012. PMID: 22504141. DOI: 10.1038/leu.2012.104
    OpenUrlCrossRefPubMed
  12. ↵
    1. Baccarani M,
    2. Deininger MW,
    3. Rosti G,
    4. Hocchaus A,
    5. Soverini S,
    6. Apperley JF,
    7. Cervantes F,
    8. Clark RE,
    9. Cortes JE,
    10. Guilhot F,
    11. Hjorth-Hansen H,
    12. Hughes TP,
    13. Kantarjian HM,
    14. Kim DW,
    15. Larson RA,
    16. Lipton JH,
    17. Mahon FX,
    18. Martinelli G,
    19. Mayer J,
    20. Müller MC,
    21. Niederwieser D,
    22. Pane F,
    23. Radich JP,
    24. Rousselot P,
    25. Saglio G,
    26. Sauβele S,
    27. Schiffer C,
    28. Silver R,
    29. Simonsson B,
    30. Steegmann JL,
    31. Goldman JM,
    32. Hehlmann R
    : European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6): 872-884, 2013. PMID: 23803709. DOI: 10.1182/blood-2013-05-501569
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. National Cancer Institute
    : Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. DOI: 10.1080/00140139.2010.489653
  14. ↵
    1. Kalmanti L,
    2. Saussele S,
    3. Lauseker M,
    4. Müller MC,
    5. Dietz CT,
    6. Heinrich L,
    7. Hanfstein B,
    8. Proetel U,
    9. Fabarius A,
    10. Krause SW,
    11. Rinaldetti S,
    12. Dengler J,
    13. Falge C,
    14. Oppliger-Leibundgut E,
    15. Burchert A,
    16. Neubauer A,
    17. Kanz L,
    18. Stegelmann F,
    19. Pfreundschuh M,
    20. Spiekermann K,
    21. Scheid C,
    22. Pfirrmann M,
    23. Hochhaus A,
    24. Hasford J,
    25. Hehlmann R
    : Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 29(5): 1123-1132, 2015. PMID: 25676422. DOI: 10.1038/leu.2015.36
    OpenUrlCrossRefPubMed
    1. Cortes JE,
    2. Saglio G,
    3. Kantarjian HM,
    4. Baccarani M,
    5. Mayer J,
    6. Boqué C,
    7. Shah NP,
    8. Chuah C,
    9. Casanova L,
    10. Bradley-Garelik B,
    11. Manos G,
    12. Hochhaus A
    : Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-Naïve chronic myeloid leukemia patients trial. J Clin Oncol 34(20): 2333-2340, 2016. PMID: 27217448. DOI: 10.1200/JCO.2015.64.8899
    OpenUrlAbstract/FREE Full Text
    1. Hochhaus A,
    2. Saglio G,
    3. Hughes TP,
    4. Larson RA,
    5. Kim DW,
    6. Issaragrisil S,
    7. le Coutre PD,
    8. Etienne G,
    9. Dorlhiac-Llacer PE,
    10. Clark RE,
    11. Flinn IW,
    12. Nakamae H,
    13. Donohue B,
    14. Deng W,
    15. Dalal D,
    16. Menssen HD,
    17. Kantarjian HM
    : Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30(5): 1044-1054, 2016. PMID: 26837842. DOI: 10.1038/leu.2016.5
    OpenUrlCrossRefPubMed
    1. Cortes JE,
    2. Gambacorti-Passerini C,
    3. Deininger MW,
    4. Mauro MJ,
    5. Chuah C,
    6. Kim DW,
    7. Dyagil I,
    8. Glushko N,
    9. Milojkovic D,
    10. le Coutre P,
    11. Garcia-Gutierrez V,
    12. Reilly L,
    13. Jeynes-Ellis A,
    14. Leip E,
    15. Bardy-Bouxin N,
    16. Hochhaus A,
    17. Brümmendorf TH
    : Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: Results from the randomized BFORE trial. J Clin Oncol 36(3): 231-237, 2018. PMID: 29091516. DOI: 10.1200/JCO.2017.74.7162
    OpenUrlCrossRef
  15. ↵
    1. Cortes JE,
    2. Kim DW,
    3. Pinilla-Ibarz J,
    4. le Coutre PD,
    5. Paquette R,
    6. Chuah C,
    7. Nicolini FE,
    8. Apperley JF,
    9. Khoury HJ,
    10. Talpaz M,
    11. DeAngelo DJ,
    12. Abruzzese E,
    13. Rea D,
    14. Baccarani M,
    15. Müller MC,
    16. Gambacorti-Passerini C,
    17. Lustgarten S,
    18. Rivera VM,
    19. Haluska FG,
    20. Guilhot F,
    21. Deininger MW,
    22. Hochhaus A,
    23. Hughes TP,
    24. Shah NP,
    25. Kantarjian HM
    : Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 132(4): 393-404, 2018. PMID: 29567798. DOI: 10.1182/blood-2016-09-739086
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Efficace F,
    2. Stagno F,
    3. Iurlo A,
    4. Breccia M,
    5. Cottone F,
    6. Bonifacio M,
    7. Abruzzese E,
    8. Castagnetti F,
    9. Caocci G,
    10. Crugnola M,
    11. Capodanno I,
    12. Martino B,
    13. Tiribelli M,
    14. Patriarca A,
    15. Gozzini A,
    16. Pregno P,
    17. Saussele S,
    18. Cascavilla N,
    19. Fozza C,
    20. Bergamaschi M,
    21. Binotto G,
    22. Vignetti M,
    23. Rosti G
    : Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. Leukemia 34(2): 488-498, 2020. PMID: 31477798. DOI: 10.1038/s41375-019-0563-0
    OpenUrl
  17. ↵
    1. Kim DW,
    2. Saussele S,
    3. Williams LA,
    4. Mohamed H,
    5. Rong Y,
    6. Zyczynski T,
    7. Pinilla-Ibarz J,
    8. Abruzzese E
    : Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study. Ann Hematol 97(8): 1357-1367, 2018. PMID: 29556695. DOI: 10.1007/s00277-018-3295-8
    OpenUrl
  18. ↵
    1. Khoury HJ,
    2. Goldberg SL,
    3. Mauro MJ,
    4. Stone MJ,
    5. Deininger MW,
    6. Bradley-Garelik MB,
    7. Mohamed H,
    8. Guilhot F
    : Cross-intolerance with dasatinib among imatinib-intolerant patients with chronic phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 16(6): 341-349, 2016. PMID: 27133948. DOI: 10.1016/j.clml.2016.03.004
    OpenUrl
  19. ↵
    1. Giles FJ,
    2. Le Coutre PD,
    3. Pinilla-Ibarz J,
    4. Larson RA,
    5. Gattermann N,
    6. Ottmann OG,
    7. Hochhaus A,
    8. Radich JP,
    9. Saglio G,
    10. Hughes TP,
    11. Martinelli G,
    12. Kim DW,
    13. Novick S,
    14. Gillis K,
    15. Fan X,
    16. Cortes J,
    17. Baccarani M,
    18. Kantarjian HM
    : Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 27(1): 107-112, 2013. PMID: 22763385. DOI: 10.1038/leu.2012.181
    OpenUrlCrossRefPubMed
    1. Shah NP,
    2. Rousselot P,
    3. Schiffer C,
    4. Rea D,
    5. Cortes JE,
    6. Milone J,
    7. Mohamed H,
    8. Healey D,
    9. Kantarjian H,
    10. Hochhaus A,
    11. Saglio G
    : Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol 91(9): 869-874, 2016. PMID: 27192969. DOI: 10.1002/ajh.24423
    OpenUrlCrossRefPubMed
  20. ↵
    1. Gambacorti-Passerini C,
    2. Brümmendorf TH,
    3. Kim DW,
    4. Turkina AG,
    5. Masszi T,
    6. Assouline S,
    7. Durrant S,
    8. Kantarjian HM,
    9. Khoury HJ,
    10. Zaritskey A,
    11. Shen ZX,
    12. Jin J,
    13. Vellenga E,
    14. Pasquini R,
    15. Mathews V,
    16. Cervantes F,
    17. Besson N,
    18. Turbull K,
    19. Leip E,
    20. Kelly V,
    21. Cortes JE
    : Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol 89(7): 732-742, 2014. PMID: 24711212. DOI: 10.1002/ajh.23728
    OpenUrlCrossRefPubMed
  21. ↵
    1. Hiwase D,
    2. Tan P,
    3. D'Rozario J,
    4. Taper J,
    5. Powell A,
    6. Irving I,
    7. Wright M,
    8. Branford S,
    9. Yeung DT,
    10. Anderson L,
    11. Gervasio O,
    12. Levetan C,
    13. Roberts W,
    14. Solterbeck A,
    15. Traficante R,
    16. Hughes T
    : Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study. Leuk Res 67: 109-115, 2018. PMID: 29494928. DOI: 10.1016/j.leukres.2018.02.013
    OpenUrl
  22. ↵
    1. Hughes TP,
    2. Leber B,
    3. Cervantes F,
    4. Spector N,
    5. Pasquini R,
    6. Clementino NCD,
    7. Schwarer AP,
    8. Dorlhiac-Llacer PE,
    9. Mahon FX,
    10. Rea D,
    11. Guerci-Bresler A,
    12. Kamel-Reid S,
    13. Bendit I,
    14. Acharya S,
    15. Glynos T,
    16. Dalal D,
    17. Branford S,
    18. Lipton JH
    : Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: Final ENESTcmr randomized trial results. Leukemia 31(11): 2529-2531, 2017. PMID: 28862704. DOI: 10.1038/leu.2017.247
    OpenUrl
  23. ↵
    1. Ishikawa J,
    2. Matsumura I,
    3. Kawaguchi T,
    4. Kuroda J,
    5. Nakamae H,
    6. Miyamoto T,
    7. Matsuoka KI,
    8. Shibayama H,
    9. Hino M,
    10. Hirase C,
    11. Kamimura T,
    12. Shimose T,
    13. Akashi K,
    14. Kankura Y
    : Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial). Int J Hematol 107(5): 535-540, 2018. PMID: 29362980. DOI: 10.1007/s12185-018-2401-y
    OpenUrl
  24. ↵
    1. Visani G,
    2. Breccia M,
    3. Gozzini A,
    4. Specchia G,
    5. Montefusco E,
    6. Morra E,
    7. Annunziata M,
    8. Camera A,
    9. Cavazzini F,
    10. Stagno F,
    11. Pregno P,
    12. Usala E,
    13. Santini V,
    14. Piccaluga PP,
    15. Isidori A
    : Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. Am J Hematol 85(12): 960-963, 2010. PMID: 2106985. DOI: 10.1002/ajh.21871
    OpenUrlCrossRefPubMed
  25. ↵
    1. Latagliata R,
    2. Breccia M,
    3. Castagnetti F,
    4. Stagno F,
    5. Luciano L,
    6. Gozzini A,
    7. Ulisciani S,
    8. Cavazzini F,
    9. Annunziata M,
    10. Sorà F,
    11. Rossi AR,
    12. Pregno P,
    13. Montefusco E,
    14. Abruzzese E,
    15. Crisà E,
    16. Musto P,
    17. Tiribelli M,
    18. Binotto G,
    19. Occhini U,
    20. Feo C,
    21. Vigneri P,
    22. Santini V,
    23. Fava C,
    24. Rosti G,
    25. Alimena G
    : Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. Leuk Res 35(9): 1164-1169, 2011. PMID: 21705080. DOI:10.1016/j.leukres.2011.05.015
    OpenUrlPubMed
  26. ↵
    1. Massimino M,
    2. Stella S,
    3. Tirrò E,
    4. Consoli ML,
    5. Pennisi MS,
    6. Puma A,
    7. Vitale SR,
    8. Romano C,
    9. Zammit V,
    10. Stagno F,
    11. Di Raimondo F,
    12. Manzella L
    : Efficacy of dasatinib in a very elderly CML patient expressing a rare E13a3 Bcr-Abl1 fusion transcrpit: a case report. Anticancer Res 39(7): 3949-3954, 2019. PMID: 31262926. DOI: 10.21873/anticanres.13548
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 40 (9)
Anticancer Research
Vol. 40, Issue 9
September 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
7 + 11 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients
UROS MARKOVIC, ANNA BULLA, SALVATORE LEOTTA, STEFANIA STELLA, MARIA LETIZIA CONSOLI, LOREDANA TAMBÈ, CONCETTA CONTICELLO, FRANCESCO DI RAIMONDO, FABIO STAGNO
Anticancer Research Sep 2020, 40 (9) 5313-5317; DOI: 10.21873/anticanres.14538

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients
UROS MARKOVIC, ANNA BULLA, SALVATORE LEOTTA, STEFANIA STELLA, MARIA LETIZIA CONSOLI, LOREDANA TAMBÈ, CONCETTA CONTICELLO, FRANCESCO DI RAIMONDO, FABIO STAGNO
Anticancer Research Sep 2020, 40 (9) 5313-5317; DOI: 10.21873/anticanres.14538
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results and Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial
  • Assessment of Breakthrough Cancer Pain Among Female Patients With Cancer: Knowledge, Management and Characterization in the IOPS-MS Study
  • Low-dose Apalutamide in Non-metastatic Castration-resistant Prostate Cancer: A Case Series
Show more Clinical Studies

Similar Articles

Keywords

  • imatinib
  • chronic myeloid leukemia
  • dasatinib
  • second-line treatment
  • TKI
  • BCR-ABL1
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire